LeadingBiotech: Cancer Advance is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Theodore (Ted) Ashburn, M.D., Ph.D.
President and CEO at Oncorus, Inc.


Before becoming Oncorus’ President, CEO and a member of its Board of Directors, Ted was Head of Oncology Development at Moderna Therapeutics where he was responsible for overall design, integration and execution of Moderna’s clinical-stage oncology programs. Prior to this role, he led the development of Moderna’s Personalized Cancer Vaccine programs. Previously, Ted was Senior Vice President of Product Strategy and Operations at Dicerna Pharmaceuticals and also the Global Product Head for Leukine® (sargramostim) and Elitek®/Fasturtec® (rasburicase) for Sanofi Oncology. In this latter role, Dr. Ashburn provided global leadership for R&D and global marketing and led regional commercial teams to identify, develop, prioritize and execute new commercialization and life-cycle management strategies to drive growth. He was also responsible for negotiating and implementing Sanofi’s 2013 supply, stockpiling and R&D contract with the U.S. Government’s Biomedical Advanced Research and Development Authority (BARDA).

Ted joined Sanofi Oncology from Genzyme’s Corporate Development group where he led business development efforts for several of Genzyme’s franchises including transplant, oncology and rare diseases and was responsible for Genzyme’s 2009 deal with ViroPharma. Prior to joining Genzyme, he worked for privately held Dynogen Pharmaceuticals, Inc. and the venture capital firm Oxford Bioscience Partners. While at Oxford he co-founded both Dynogen and BrainCells, Inc. and led investments in Alantos Pharmaceuticals (acquired in June, 2007 by Amgen for $300 million in cash) and superDimension, Ltd. (acquired by Covidien in March, 2012 for more than $300 million). Before joining Oxford, Ted started his career at Pfizer Inc. where he was involved in the analysis of several acquisition and new business opportunities including Pfizer’s acquisition of Warner-Lambert in 2001.

Ted graduated magna cum laude from Ball State University where he studied chemistry and computer science. He earned his M.D. from Harvard Medical School and Ph.D. in organic chemistry from the Massachusetts Institute of Technology.

Theodore (Ted) Ashburn, M.D., Ph.D.'s Network

Agenda Sessions

  • Therapeutic Focus: Oncolytic Viruses


Speakers at this event